Abivax SANASDAQ:ABVX
- LAST PRICE8.7000
- TODAY'S CHANGE (%)-0.1600 (-1.8059%)
- Bid / Lots8.1200/ 1
- Ask / Lots11.0700/ 5
- Open / Previous Close8.8000 / 8.8600
- Day Range
- 52 Week Range
- Volume75,729
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABVX |
|---|---|---|
| 09:32 ET | 913 | 8.8 |
| 09:33 ET | 300 | 8.69 |
| 09:46 ET | 2055 | 8.78 |
| 09:48 ET | 100 | 8.765 |
| 09:55 ET | 800 | 8.76 |
| 10:06 ET | 800 | 8.73 |
| 10:13 ET | 800 | 8.695 |
| 10:18 ET | 100 | 8.695 |
| 10:22 ET | 100 | 8.695 |
| 10:54 ET | 1000 | 8.69 |
| 10:56 ET | 200 | 8.69 |
| 10:58 ET | 100 | 8.69 |
| 11:16 ET | 744 | 8.6975 |
| 11:18 ET | 800 | 8.69 |
| 11:20 ET | 100 | 8.66 |
| 11:30 ET | 300 | 8.675 |
| 11:32 ET | 100 | 8.68 |
| 11:59 ET | 300 | 8.71 |
| 12:01 ET | 6780 | 8.69 |
| 12:03 ET | 200 | 8.69 |
| 12:06 ET | 100 | 8.69 |
| 12:08 ET | 7652 | 8.685 |
| 12:19 ET | 500 | 8.735 |
| 12:21 ET | 1020 | 8.73 |
| 12:26 ET | 243 | 8.73 |
| 12:30 ET | 100 | 8.73 |
| 12:39 ET | 100 | 8.715 |
| 12:46 ET | 1400 | 8.755 |
| 12:48 ET | 129 | 8.75 |
| 01:08 ET | 117 | 8.745 |
| 01:18 ET | 104 | 8.74 |
| 01:24 ET | 800 | 8.725 |
| 01:29 ET | 100 | 8.7 |
| 01:33 ET | 14622 | 8.56 |
| 01:36 ET | 300 | 8.625 |
| 01:56 ET | 234 | 8.6385 |
| 02:05 ET | 100 | 8.51 |
| 02:09 ET | 700 | 8.55 |
| 02:14 ET | 100 | 8.55 |
| 02:30 ET | 600 | 8.59 |
| 02:41 ET | 146 | 8.58 |
| 02:45 ET | 100 | 8.58 |
| 02:57 ET | 126 | 8.59 |
| 03:03 ET | 100 | 8.54 |
| 03:06 ET | 500 | 8.6399 |
| 03:12 ET | 100 | 8.585 |
| 03:15 ET | 100 | 8.63 |
| 03:17 ET | 200 | 8.6152 |
| 03:19 ET | 2586 | 8.67 |
| 03:21 ET | 200 | 8.665 |
| 03:28 ET | 100 | 8.665 |
| 03:32 ET | 100 | 8.665 |
| 03:33 ET | 100 | 8.665 |
| 03:42 ET | 100 | 8.66 |
| 03:50 ET | 1018 | 8.675 |
| 03:51 ET | 582 | 8.65 |
| 03:53 ET | 100 | 8.695 |
| 03:55 ET | 600 | 8.73 |
| 03:57 ET | 512 | 8.695 |
| 04:00 ET | 6887 | 8.7 |
Nov 19, 2024
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq, from 4:30PM ET on Tuesday Nov 19, 2024 by Dow Jones
4:30PM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
Abivax presents third quarter 2024 key financial information, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: Abivax presents third quarter 2024 key financial information, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Bd Observer & Advisor to Abivax, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Industry Peers
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abivax SA | --- | 0.0x | --- |
Company Information
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Contact Information
- Headquarters
- 7-11 Boulevard HaussmannPARIS, France 75009
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Sylvie Gregoire
- Chief Executive Officer
- Marc De Garidel
- Chief Financial Officer, Board Secretary
- Didier Blondel
- Chief People Officer, Chief Compliance Officer
- Ida Hatoum
- Chief Scientific Officer
- Didier Scherrer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
